High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in Emergency Department Patients With Cardiogenic Pulmonary Edema: A Randomized Controlled Trial

Makdee, Onlak; Monsomboon, Apichaya; Surabenjawong, Usapan; Praphruetkit, Nattakarn; Chaisirin, Wansiri; Chakorn, Tipa; Permpikul, Chairat; Thiravit, Phakphoom; Nakornchai, Tanyaporn

doi:10.1016/j.annemergmed.2017.03.028

Cited by 110 publications

(118 citation statements)

References 20 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Makdee et al . () showed a significant decrease in respiratory rate after 1 hour in the HOT group compared to conventional oxygen therapy group in human patients with cardiogenic pulmonary oedema. Another study comparing respiratory rate between patients under nasal oxygen therapy or HOT in a more homogeneous population would be of great interest to differentiate between effects of time versus effects of treatment.…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

Prospective pilot study for evaluation of high‐flow oxygen therapy in dyspnoeic dogs: the HOT‐DOG study

Pouzot‐Nevoret

Hocine

Nègre

et al. 2019

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To describe the use, effectiveness and tolerance of high‐flow oxygen therapy in dyspnoeic dogs. Materials and Methods Prospectively, dogs in acute respiratory distress admitted to an intensive care unit between January and May 2018 that failed to respond to nasal oxygen therapy and medical stabilisation after 30 minutes were transitioned to high‐flow oxygen therapy. High‐flow oxygen therapy, delivered an inspired oxygen fraction of 100% using an air/oxygen blender, active humidifier, single warmed tube and specific nasal cannula. Respiratory rate, pulse oximetry (SpO2), heart rate and a tolerance score were assessed every 15 minutes from T0 (under nasal oxygen) to 1 hour (T60), and PaO2 and PaCO2 at T0 and T60. Complications were recorded for each dog. Results Eleven dogs were included. At T60, PaO2, flow rate and SpO2 were significantly greater than at T0 (171 ± 123 versus 73 ± 24 mmHg; P=0.015; 18 ±12 L/minute versus 3.2 ± 2.0 L/minute, P<0.01; 97.7 ±2.3% versus 91.6 ±7.2%, P=0.03, respectively). There was no significant difference in PaCO2, respiratory rate or heart rate between T0 and T60. Tolerance was excellent, and there were no complications. Clinical Significance High‐flow oxygen therapy improves markers of oxygenation in dyspnoeic dogs and is an effective means to deliver oxygen with comfort and minimal complications.

show abstract

Section: Discussionmentioning

confidence: 86%

“…, Makdee et al . ). In our study, six dogs had a decrease in respiratory rate between T 0 and T 60 , but with variable changes over time (Fig ).…”

Section: Discussionmentioning

confidence: 97%

Prospective pilot study for evaluation of high‐flow oxygen therapy in dyspnoeic dogs: the HOT‐DOG study

Pouzot‐Nevoret

Hocine

Nègre

et al. 2019

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…An important sign is the degree of perceived discomfort – often referred to as ‘work of breathing’. This is poorly captured by current observation tools, and a numerical or visual analogue scale may be used . As the patient stabilises and starts to improve, monitoring can be reduced to simple oximetry and usual ward observations.…”

Section: How Do I Monitor Hhfnc?mentioning

confidence: 99%

“…This is poorly captured by current observation tools, and a numerical or visual analogue scale may be used. 10,20 As the patient stabilises and starts to improve, monitoring can be reduced to simple oximetry and usual ward observations. It is important to stress that the observation chart should record measured SaO 2 , while the FiO 2 reading from the control box is noted as a setting.…”

Section: How Do I Monitor Hhfnc?mentioning

confidence: 99%

How to use humidified high‐flow nasal cannula in breathless adults in the emergency department

Baker

Greaves

2019

Emerg Medicine Australasia

View full text Add to dashboard Cite

“…Pulmonary congestion was assessed on conventional chest X-ray on admission (Table S1). 7 Follow-up information was collected mainly by reviewing the hospital charts, and additional information was collected through contact with patients, their family members, and/or referring physicians by sending letters asking survival status, symptoms, and subsequent hospitalization. The short-term outcome measures were inhospital outcomes including 24-h urinary output; days to decongestion on chest X-ray; in-hospital death; change in creatinine from admission to discharge; and symptoms (i.e., congestion on chest X-ray, and pleural effusion on chest X-ray) remaining at discharge.…”

Section: Data Collection and Definitionsmentioning

confidence: 99%

Effects of Carperitide on Degree of Pulmonary Congestion in Treatment of Acute Heart Failure

Kawase

Hata

Tada

et al. 2018

Circ J

View full text Add to dashboard Cite

12 with insufficient data, 57 with acute coronary syndrome, 77 with admission systolic blood pressure (SBP) <100 mmHg, and 23 with end-stage renal disease requiring hemodialysis. Consequently, 742 patients were included in the final analysis ( Figure 1A). Patients who started to receive carperitide ≤24 h after admission were assigned to the carperitide group. The carperitide group consisted of 219 patients, 216 (98.6%) of whom started to receive carperitide at the time of admission. In the non-carperitide group, which consisted of 523 patients, only 25 patients (4.8%) received carperitide >24 h after admission, and the remainder did not receive carperitide at all.We compared the short-and long-term outcomes between the carperitide and non-carperitide groups, stratified according to the degree of pulmonary congestion. Of the 742 patients, 358 had moderate-severe pulmonary congestion (carperitide group, n=140; 39.1%; non-carperitide group, n=218; 60.9%) and 384 had no-mild pulmonary congestion (carperitide group, n=79; 20.6%; non-carperitide group, n=305; 79.4%; Figure 1A).The effects of carperitide were assessed based on an as-treated analysis. Follow-up was commenced on the day of admission.The study protocol was approved by the Institutional Review Board. The study was conducted in accordance with the provisions of the Declaration of Helsinki and the A cute heart failure (AHF) is the most common cause of hospitalization in many countries. It is associated with high in-hospital and post-discharge mortality rates and rehospitalization rates. A few promising drugs for AHF have been developed and are currently under investigation, but they have yet to fully improve clinical outcome.Since the launch of carperitide in 1995, a low-dose regimen has been widely used for treating AHF in Japan, following previous Japanese studies showing that its cardiorenal protective effect improves prognosis. 1-4 Recently, carperitide was found to increase the in-hospital mortality rate in AHF patients, and the effects of carperitide on the prognosis of AHF are currently controversial. 5, 6 We hypothesized that carperitide is effective in treating AHF with pulmonary congestion by promoting diuresis and vasodilation. The aim of this study was to investigate the effects of carperitide in AHF according to the degree of pulmonary congestion. Background: Carperitide is used to treat acute heart failure (AHF) in Japan. Whether the degree of pulmonary congestion is associated with the effects of carperitide on AHF is unclear. Methods Study Design and Subjects

show abstract

High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in Emergency Department Patients With Cardiogenic Pulmonary Edema: A Randomized Controlled Trial

Abstract: In patients with cardiogenic pulmonary edema in the ED, high-flow nasal cannula therapy may decrease the severity of dyspnea during the first hour of treatment.

Cited by 110 publications

References 20 publications

Prospective pilot study for evaluation of high‐flow oxygen therapy in dyspnoeic dogs: the HOT‐DOG study

Prospective pilot study for evaluation of high‐flow oxygen therapy in dyspnoeic dogs: the HOT‐DOG study

How to use humidified high‐flow nasal cannula in breathless adults in the emergency department

Effects of Carperitide on Degree of Pulmonary Congestion in Treatment of Acute Heart Failure

Contact Info

Product

Resources

About